JP2006527741A5 - - Google Patents

Download PDF

Info

Publication number
JP2006527741A5
JP2006527741A5 JP2006516231A JP2006516231A JP2006527741A5 JP 2006527741 A5 JP2006527741 A5 JP 2006527741A5 JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006527741 A5 JP2006527741 A5 JP 2006527741A5
Authority
JP
Japan
Prior art keywords
hfddde
hexapeptide
active ingredient
preventing
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006516231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006527741A (ja
Filing date
Publication date
Priority claimed from FI20030923A external-priority patent/FI20030923A7/fi
Priority claimed from FI20040616A external-priority patent/FI20040616A0/fi
Application filed filed Critical
Priority claimed from PCT/FI2004/000376 external-priority patent/WO2004110478A1/en
Publication of JP2006527741A publication Critical patent/JP2006527741A/ja
Publication of JP2006527741A5 publication Critical patent/JP2006527741A5/ja
Withdrawn legal-status Critical Current

Links

JP2006516231A 2003-06-19 2004-06-21 細胞遊走の阻害剤 Withdrawn JP2006527741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030923A FI20030923A7 (fi) 2003-06-19 2003-06-19 Leukosyytti-proMMP-9/beta2-integriinikompleksin inhibiittorit
FI20040616A FI20040616A0 (fi) 2004-04-29 2004-04-29 Solumigraation inhibiittorit
PCT/FI2004/000376 WO2004110478A1 (en) 2003-06-19 2004-06-21 Inhibitors of cell migration

Publications (2)

Publication Number Publication Date
JP2006527741A JP2006527741A (ja) 2006-12-07
JP2006527741A5 true JP2006527741A5 (enExample) 2007-08-02

Family

ID=33553915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006516231A Withdrawn JP2006527741A (ja) 2003-06-19 2004-06-21 細胞遊走の阻害剤
JP2006516230A Withdrawn JP2006527740A (ja) 2003-06-19 2004-06-21 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006516230A Withdrawn JP2006527740A (ja) 2003-06-19 2004-06-21 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤

Country Status (3)

Country Link
EP (2) EP1644031A1 (enExample)
JP (2) JP2006527741A (enExample)
WO (2) WO2004110478A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595935A1 (en) * 2005-01-31 2006-08-03 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic peptides derived from urokinase plasminogen activator receptor
EP1924595A2 (en) * 2005-08-12 2008-05-28 Cartela R & D AB Novel peptides and uses thereof
GB2429012A (en) * 2005-08-12 2007-02-14 Cartela Ab Polypeptides capable of binding an integrin I-domain.
ES2464731T3 (es) 2008-11-04 2014-06-03 Index Pharmaceuticals Ab Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
WO2018175749A2 (en) 2017-03-22 2018-09-27 Children's Medical Center Corporation Lrp1 binding agents and uses thereof
CN110691606A (zh) 2017-03-22 2020-01-14 儿童医学中心公司 Prss2抑制

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US20030022835A1 (en) * 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
GB9809764D0 (en) * 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
ES2327812T3 (es) * 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
WO2003091391A2 (en) * 2002-04-23 2003-11-06 Duke University Atherosclerotic phenotype determinative genes and methods for using the same

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
JP2004210767A5 (enExample)
JP2002532112A5 (enExample)
WO2008011169A3 (en) Controlled release formulations and associated methods
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
DE50313653D1 (de) Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
JP2002511411A5 (enExample)
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
JP2005518413A5 (enExample)
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
UA88477C2 (ru) Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
CL2004000416A1 (es) Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa.
JP2007523135A5 (enExample)
JP2006517944A5 (enExample)
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
JP2008518699A5 (enExample)
WO2004096125A3 (en) Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
ITRM20040223A1 (it) Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.